Efficacy of a growth hormone-releasing peptide mimetic in cardiac ischemia/reperfusion injury

Abstract The cardioprotective efficacy of the pyrazolinone–piperidine dipeptide growth hormone secretagogue (GHS) CP-424,391 was studied in an in vivo rabbit model of ischemia and reperfusion. CP-424,391 was administered at 25 mg/kg p.o.×7 days. Ischemia was induced by left coronary artery occlusion for 30 min, after which the heart was reperfused for 2 h. At the end of reperfusion, animals were euthanized and the infarct size was determined. The area at risk of infarct was not different between the control (45.8±3.7%, n =6) and CP-424,391-treated groups (36.9±4.3%, n =11). The infarct size of the control animals was 49.5±7.1% and was significantly ( P